[Serotonin and cardiovascular diseases. Pathophysiology and significance of serotonin antagonists].
Lüscher
T F
TF
Departement für Innere Medizin, Kantonsspital Basel.
Tanner
F C
FC
Bühler
F R
FR
D000368:Aged; D000818:Animals; D001157:Arterial Occlusive Diseases / Q000188:drug therapy / Q000503:physiopathology; D001792:Blood Platelets / Q000502:physiology; D002318:Cardiovascular Diseases / Q000188:drug therapy / Q000503:physiopathology*; D002561:Cerebrovascular Disorders / Q000188:drug therapy / Q000503:physiopathology; D001026:Coronary Artery Bypass; D003327:Coronary Disease / Q000188:drug therapy / Q000503:physiopathology / Q000601:surgery; D004730:Endothelium, Vascular / Q000502:physiology; D005128:Eye Diseases / Q000188:drug therapy; D005260:Female; D006801:Humans; D006937:Hypercholesterolemia / Q000503:physiopathology; D006973:Hypertension / Q000188:drug therapy / Q000503:physiopathology; D007650:Ketanserin / Q000627:therapeutic use; D008297:Male; D051381:Rats; D012701:Serotonin / Q000494:pharmacology / Q000502:physiology*; D012702:Serotonin Antagonists / Q000627:therapeutic use*
D012702:Serotonin Antagonists; D012701:Serotonin; D007650:Ketanserin
Serotonin und kardiovaskuläre Erkrankungen. Pathophysiologie und Bedeutung von Serotoninantagonisten.